
Sonoma Pharmaceuticals SNOA
€ 3.20
-1.32%
Quartalsbericht 2025-Q3
hinzugefügt 04.11.2025
Sonoma Pharmaceuticals Kurzfristige Verbindlichkeiten 2011-2026 | SNOA
Kurzfristige Verbindlichkeiten Jährlich Sonoma Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.1 M | 3.72 M | 3.72 M | 5.82 M | 4.08 M | 4.86 M | 3.59 M | 3.26 M | 3.29 M | 3.55 M | 2.58 M | 7.57 M | 5.13 M | 4.75 M | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 7.57 M | 2.58 M | 4.29 M |
Kurzfristige Verbindlichkeiten anderer Aktien in der Arzneimittelhersteller
| Name | Kurzfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Alimera Sciences
ALIM
|
21.9 M | - | - | $ 142 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
11.4 M | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
125 M | - | - | $ 754 M | ||
|
Canopy Growth Corporation
CGC
|
94.4 M | $ 1.27 | -1.55 % | $ 137 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
2.65 M | - | 7.5 % | $ 6.35 M | ||
|
Agile Therapeutics
AGRX
|
20.8 M | - | 10.11 % | $ 58.2 M | ||
|
Catalent
CTLT
|
1.03 B | - | - | $ 11.5 B | ||
|
DURECT Corporation
DRRX
|
27 M | - | - | $ 50.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
111 M | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
539 M | - | - | $ 28.9 M | ||
|
Organogenesis Holdings
ORGO
|
77.5 M | $ 4.18 | -0.71 % | $ 550 M | ||
|
Emergent BioSolutions
EBS
|
651 M | $ 13.2 | -1.2 % | $ 676 M | ||
|
Evoke Pharma
EVOK
|
9.65 M | - | - | $ 36.6 M | ||
|
Athenex
ATNX
|
115 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
48.8 M | $ 21.52 | 0.16 % | $ 2.05 B | ||
|
Evolus
EOLS
|
63 M | $ 5.51 | -3.97 % | $ 342 M | ||
|
Harrow Health
HROW
|
49.3 M | $ 48.84 | -4.32 % | $ 1.59 B | ||
|
China Pharma Holdings
CPHI
|
5.02 M | $ 1.34 | -1.48 % | $ 23.4 M | ||
|
Tilray
TLRY
|
433 M | $ 9.36 | 2.52 % | $ 5.78 B | ||
|
Jupiter Wellness
JUPW
|
9.4 M | - | - | $ 33.6 M | ||
|
Bausch Health Companies
BHC
|
4.3 B | $ 7.55 | -2.96 % | $ 2.75 B | ||
|
Veru
VERU
|
11.9 M | $ 2.38 | 3.03 % | $ 321 M | ||
|
Lannett Company
LCI
|
105 M | - | 1.15 % | $ 7.11 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
31.6 M | $ 4.86 | 0.62 % | $ 68.3 M | ||
|
Neoleukin Therapeutics
NLTX
|
23 M | - | - | $ 193 M | ||
|
Pacira BioSciences
PCRX
|
310 M | $ 23.32 | -10.38 % | $ 1.08 B | ||
|
PetIQ
PETQ
|
190 M | - | 1.64 % | $ 400 M | ||
|
Perrigo Company plc
PRGO
|
1.04 B | $ 14.96 | 1.73 % | $ 2.06 B | ||
|
ProPhase Labs
PRPH
|
16.1 M | - | - | $ 5.07 M | ||
|
Recro Pharma
REPH
|
50 M | - | -4.76 % | $ 65.3 M | ||
|
Radius Health
RDUS
|
94.8 M | - | - | $ 1.42 B | ||
|
Rockwell Medical
RMTI
|
16.6 M | $ 0.95 | -2.72 % | $ 22.2 M | ||
|
cbdMD
YCBD
|
8.62 M | $ 1.04 | -4.59 % | $ 4.49 M | ||
|
Relmada Therapeutics
RLMD
|
12.2 M | $ 4.4 | -0.68 % | $ 132 M | ||
|
OptiNose
OPTN
|
177 M | - | - | $ 1.08 B | ||
|
Assertio Holdings
ASRT
|
93.4 M | $ 9.32 | 0.11 % | $ 662 M | ||
|
PLx Pharma
PLXP
|
11.9 M | - | -27.8 % | $ 2.56 M | ||
|
Solid Biosciences
SLDB
|
30.3 M | $ 5.31 | - | $ 217 M | ||
|
SCYNEXIS
SCYX
|
16.3 M | $ 0.67 | 1.28 % | $ 32.1 M | ||
|
Tricida
TCDA
|
29.5 M | - | - | $ 3.25 M | ||
|
TherapeuticsMD
TXMD
|
6.85 M | $ 2.09 | 1.46 % | $ 21.8 M | ||
|
Viatris
VTRS
|
6.75 B | $ 12.73 | 1.03 % | $ 15.4 B | ||
|
Zomedica Corp.
ZOM
|
9.03 M | - | -0.21 % | $ 98 M |